Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3325656 · 1 trial · 1 indication
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| Placebo (Part A) | PLACEBO_COMPARATOR | Single oral dose of placebo (sugar pill) administered to healthy participants in up to 1 study period in Part A |
| LY3325656 (Part A) | EXPERIMENTAL | Single ascending dose of LY3325656 administered orally to healthy participants in up to 3 study periods in Part A |
| Placebo (Part B) | PLACEBO_COMPARATOR | Single oral dose of placebo (sugar pill) administered to participants with T2DM in 1 study period in Part B |
| LY3325656 (Part B) | EXPERIMENTAL | Single oral dose of LY3325656 administered to participants with T2DM in 1 study period in Part B |
| Liraglutide (Part B) | ACTIVE_COMPARATOR | Single subcutaneous dose of liraglutide administered to participants with T2DM in 1 study period in Part B |
| LY3325656 + Sitagliptin (Part B) | EXPERIMENTAL | Single oral dose of LY3325656 and sitagliptin administered to participants with T2DM in 1 study period in Part B |
| Name | Type | Description |
|---|---|---|
| LY3325656 | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
| Liraglutide | DRUG | Administered subcutaneously |
| Sitagliptin | DRUG | Administered orally |
Inclusion Criteria: For all participants: * Must be a male, or a female who cannot become pregnant, and who is either a healthy participant, or who has type 2 diabetes * Have a screening body mass index (BMI) of at least 18.5 kilograms per square meter (kg/m²) * Have blood pressure, pulse rate, bl...
LY3325656 is an investigational small molecule being studied for the treatment of Type 2 Diabetes Mellitus. It is in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being evaluated in a clinical trial involving healthy participants and those with Type 2 Diabetes.
LY3325656 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The drug is currently in Phase 1 clinical development for the treatment of Type 2 Diabetes Mellitus.
LY3325656 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of Type 2 Diabetes Mellitus, with one completed Phase 1 trial involving 80 participants.
LY3325656 has one completed Phase 1 clinical trial, identified by the National Clinical Trial number NCT03115099. The study, titled "A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes," enrolled 80 participants in Singapore and included healthy volunteers.
LY3325656 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for the treatment of Type 2 Diabetes Mellitus. The drug has completed one Phase 1 trial, but it remains in clinical development and has not received regulatory approval.